Determining E&L risk from single-use components can be used to build the level of extractable profiling and PERLs.
Somasundaram Gopalakrishnan
Advertisement
Somasundaram Gopalakrishnan, is senior consultant, Global Biopharm Center of Excellence, Merck Pte. Ltd.
Articles by Somasundaram Gopalakrishnan
The evolution of therapeutic modalities drives the adoption of single-use technologies.
Advertisement
Latest Updated Articles
Review of SUT Adoption in Biopharma ManufacturingMarch 15th 2024
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
France Remains One of Europe’s Leading Biotech Funding Hubs
2
CPHI Pharma Award Winner: Drug Delivery, Devices, & Packaging
3
Investing in Protecting Pharma Products
4
Signs Point to FDA Shelving Priority Voucher Pilot, Stalling Fast-Track Drug Reviews
5